Drug Delivery Business

Insulet up on Street-beating Q2, raised guidance

By

InsuletInsulet (NSDQ:PODD) shares ticked up today on second-quarter results that topped the consensus forecast.

The Acton, Mass.-based wearable insulin delivery system developer posted profits of $14.4 million, or 22¢ per share, on sales of $226.3 million for the three months ended June 30, 2020, for a bottom-line gain of nearly ten times as much as last year’s second-quarter profits on sales growth of 27.8%.

Get the full story at our sister site, Drug Delivery Business News.

IN CASE YOU MISSED IT

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].